Lung Neoplasms
"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LUNG.
Descriptor ID |
D008175
|
MeSH Number(s) |
C04.588.894.797.520 C08.381.540 C08.785.520
|
Concept/Terms |
Lung Neoplasms- Lung Neoplasms
- Pulmonary Neoplasms
- Neoplasms, Lung
- Lung Neoplasm
- Neoplasm, Lung
- Neoplasms, Pulmonary
- Neoplasm, Pulmonary
- Pulmonary Neoplasm
Lung Cancer- Lung Cancer
- Cancer, Lung
- Cancers, Lung
- Lung Cancers
- Pulmonary Cancer
- Cancer, Pulmonary
- Cancers, Pulmonary
- Pulmonary Cancers
- Cancer of the Lung
- Cancer of Lung
|
Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".
This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 1 | 4 | 5 | 1981 | 2 | 4 | 6 | 1982 | 5 | 0 | 5 | 1983 | 10 | 2 | 12 | 1984 | 7 | 2 | 9 | 1985 | 7 | 3 | 10 | 1986 | 9 | 0 | 9 | 1987 | 8 | 0 | 8 | 1988 | 6 | 3 | 9 | 1989 | 6 | 1 | 7 | 1990 | 9 | 5 | 14 | 1991 | 1 | 3 | 4 | 1992 | 13 | 2 | 15 | 1993 | 13 | 1 | 14 | 1994 | 6 | 7 | 13 | 1995 | 11 | 5 | 16 | 1996 | 10 | 4 | 14 | 1997 | 9 | 0 | 9 | 1998 | 13 | 1 | 14 | 1999 | 8 | 4 | 12 | 2000 | 12 | 2 | 14 | 2001 | 12 | 5 | 17 | 2002 | 20 | 9 | 29 | 2003 | 32 | 13 | 45 | 2004 | 30 | 7 | 37 | 2005 | 34 | 11 | 45 | 2006 | 31 | 12 | 43 | 2007 | 41 | 7 | 48 | 2008 | 43 | 9 | 52 | 2009 | 36 | 4 | 40 | 2010 | 44 | 4 | 48 | 2011 | 54 | 10 | 64 | 2012 | 51 | 4 | 55 | 2013 | 57 | 5 | 62 | 2014 | 50 | 6 | 56 | 2015 | 71 | 9 | 80 | 2016 | 67 | 10 | 77 | 2017 | 59 | 3 | 62 | 2018 | 73 | 6 | 79 | 2019 | 74 | 7 | 81 | 2020 | 71 | 6 | 77 | 2021 | 83 | 3 | 86 | 2022 | 39 | 0 | 39 |
To return to the timeline, click here.
Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
Beaber EF, Kamineni A, Burnett-Hartman AN, Hixon B, Kobrin SC, Li CI, Oliver M, Rendle KA, Skinner CS, Todd K, Zheng Y, Ziebell RA, Breslau ES, Chubak J, Corley DA, Greenlee RT, Haas JS, Halm EA, Honda S, Neslund-Dudas C, Ritzwoller DP, Schottinger JE, Tiro JA, Vachani A, Doria-Rose VP. Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 Aug 02; 31(8):1521-1531.
-
Baxi V, Lee G, Duan C, Pandya D, Cohen DN, Edwards R, Chang H, Li J, Elliott H, Pokkalla H, Glass B, Agrawal N, Lahiri A, Wang D, Khosla A, Wapinski I, Beck A, Montalto M. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol. 2022 11; 35(11):1529-1539.
-
Mazzone P, Dotson T, Wahidi MM, Bernstein M, Lee HJ, Feller Kopman D, Yarmus L, Whitney D, Stevenson C, Qu J, Johnson M, Walsh PS, Huang J, Lofaro LR, Bhorade SM, Kennedy GC, Spira A, Rivera MP. Clinical validation and utility of Percepta GSC for the evaluation of lung cancer. PLoS One. 2022; 17(7):e0268567.
-
Lau D, Khare S, Stein MM, Jain P, Gao Y, BenTaieb A, Rand TA, Salahudeen AA, Khan AA. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. Nat Commun. 2022 07 13; 13(1):4053.
-
Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022 11; 86(Pt 2):233-246.
-
Kalchiem-Dekel O, Falcon CJ, Bestvina CM, Liu D, Kaplanis LA, Wilhelm C, Eichholz J, Harada G, Wirth LJ, Digumarthy SR, Lee RP, Kadosh D, Mendelsohn RB, Donington J, Gainor JF, Drilon A, Lin JJ. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136.
-
Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
-
Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
-
Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
-
Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|